Spero Therapeutics, Inc. — Director's Dealing 2021

Jan 5, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Spero Therapeutics, Inc. (SPRO)
CIK: 0001701108
Period of Report: 2021-01-04

Reporting Person: Shukla Sath (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-01-04	Stock Option (right to buy)	$17.93	A	75000	Acquired	2031-01-04	Common Stock (75000)	Direct

Footnotes

F1: The shares underlying this option vest as to 25% on January 4, 2022, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting dates.